Develops and supports execution of strategic vision for multiple sclerosis (MS) and immunology franchises. Serves as commercial lead and conducts due diligence for M&A and partnership opportunities. Responsible for developing an understanding of market landscape, patient segmentation, unmet needs, product positioning, and commercial opportunity and resourcing needs for existing disease areas and strategic adjacencies. Supports franchises in delivery of the corporate strategic plan. Served as early commercial lead for internal MS & immunology development pipeline.

Led the development and implementation of reimbursement and health economics activities for the Prostate Health franchise. Developed tools and resources to support field sales teams in realizing opportunities and overcoming challenges experienced by customers. Worked with new product development teams to ensure that health economics and reimbursement needs were incorporated into development plans. Managed direct report responsible for generating and publishing novel research and evidence. Nominated for and completed internal Velocity leadership development program.

Lead assessments of external companies and adjacent markets for acquisition, investment and partnership. Managed cross-functional due diligence teams of 5-50 people. Builds investment cases based on functional diligence, working with stakeholders to articulate findings and recommendations and identify key risks and mitigations. Maintained a list of prioritized targets while managing engagement with over 100 companies. Worked with Finance, Marketing, and Strategy to develop and refine complex models. Negotiated agreements for acquisition or partnership. Ran monthly update meetings with divisional leadership. Active or past member on all divisional Franchise Leadership Teams. Executed on 6 M&A transactions including Lumenis Surgical ($1.1Bn), Augmenix ($600M), and NxThera ($400M).

Conducted strategic assessments of business development and whitespace opportunities to define clinical unmet needs of target disease areas and companies. Performed primary and secondary research to articulate disease fundamentals, quantify incidence and prevalence, identify appropriate patient segments, articulate physician perspective on treatments and the competitive landscape, and evaluate clinical trial design and outcomes. Independently managed projects, working with BD, Marketing, and Clinical to define scope, gather input, and make recommendations. Markets covered included urology, GI and cardiology.

Performed strategic and financial analysis for a broad mix of healthcare clients, including payors and pharmaceutical companies. Experience across multiple functions including strategy, business development, marketing and sales, finance, IT, and operations. Developed recommendations and presented results to C-level client leadership. Lead engagement teams and mentored junior associates. Representative experiences include:Healthcare reform implantation at multiple federal agencies• Supported CMS, IRS, and FDA in their interpretation and implementation of the Affordable Care Act (ACA)• Worked with agency leadership and bill experts to develop performance management metrics to track success• Lead weekly internal-McKinsey knowledge sharing sessions, focused on aligning on consistent interpretation of the ACA and disseminating best practices across experiences at federal agencies and commercial payersProject management office (PMO) design and implementation to manage healthcare reform• Supported creation of a PMO responsible for implementing health care reform at a commercial payor• Worked with SMEs from product design, actuary, and legal to interpret and clarify legislative requirements• Led capability building workshops and served as lead/role model for three implementation teamsDisease area and market assessment• Developed business case on allergy market, prioritizing assets by probability of clinical success, expected market acceptance, and forecasted revenues; presented recommendations to CEO of Fortune 50 company• Built P&Ls for priority targets based on interviews with physicians and payor experts and review of analyst reports